Omega-3 EPA and DHA: The REDUCE-IT Trial Proved 4g/Day Pure EPA Reduces Heart Attacks by 25%, But Standard Fish Oil Doesn't Do the Same — What Form You Take, Whether It's Oxidized, and the EPA:DHA Ratio Determines Whether You Get the Benefit or Just Expensive Burps
Updated: June 2026omega-3 supplement · omega-3 benefits · fish oil supplement · EPA DHA supplement · best omega-3 supplement · omega-3 cardiovascular · omega-3 heart health · omega-3 anti-inflammatory · fish oil vs krill oil · krill oil vs fish oil · algae oil omega-3 · vegan omega-3 · plant omega-3 · ALA vs EPA DHA · omega-3 conversion ALA · flaxseed omega-3 · walnuts omega-3 · omega-3 triglycerides · fish oil lower triglycerides · omega-3 hypertriglyceridemia · triglyceride reduction omega-3 · omega-3 LDL · fish oil LDL increase · omega-3 HDL · omega-3 blood pressure · omega-3 inflammation · EPA anti-inflammatory · omega-3 resolvin · omega-3 protectin · EPA DHA mechanism · arachidonic acid EPA ratio · AA:EPA ratio · omega-3 index · omega-3 index heart risk · optimal omega-3 index · omega-3 index 8% · REDUCE-IT trial · icosapentaenoic acid · vascepa · REDUCE-IT Bhatt 2019 · STRENGTH trial · OMACOR omega-3 · ASCEND trial · VITAL trial omega-3 · omega-3 cancer · omega-3 cognitive · DHA brain · DHA neuron membrane · DHA phospholipid · omega-3 depression · omega-3 mental health · omega-3 ADHD children · omega-3 inflammation markers · CRP omega-3 · IL-6 omega-3 · fish oil oxidation · oxidized fish oil · rancid fish oil · TOTOX value fish oil · peroxide value fish oil · anisidine value fish oil · fish oil quality · fish oil brand · triglyceride form fish oil · re-esterified triglyceride rTG · ethyl ester fish oil · phospholipid omega-3 · krill oil phospholipid · fish oil form comparison · omega-3 absorption form · omega-3 with food · omega-3 dose · how much omega-3 per day · omega-3 1g · omega-3 2g · omega-3 4g prescription · prescription omega-3 · Lovaza · Omacor · omega-3 safety · fish oil blood thinning · fish oil surgery · omega-3 and anticoagulants · omega-3 fishy burps · enteric coated fish oil
The omega-3 story is more complicated than "fish oil is good for the heart." The evidence is stratified by dose, by form, by whether the preparation is oxidized, and most crucially by which fatty acid you're measuring — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both omega-3s but they have distinct mechanisms, distinct clinical trial outcomes, and distinct optimal applications. The REDUCE-IT trial (2018, published NEJM 2019) was a watershed moment because it finally showed a 25% reduction in major adverse cardiovascular events with high-dose EPA in a well-designed RCT — something that had eluded the field for decades. But it also raised important questions, because a similarly designed trial using EPA+DHA combined (the STRENGTH trial) found no cardiovascular benefit. Understanding why requires understanding the biochemistry.
−25%
MACE reduction (REDUCE-IT) — Bhatt et al. 2019 (New England Journal of Medicine): REDUCE-IT trial; N=8,179 patients with elevated triglycerides (≥150 mg/dL) already on statins, with established CVD or diabetes plus 2+ CVD risk factors; intervention: icosapentaenoic acid (EPA) as ethyl ester (Vascepa) 4g/day (2g BID) vs mineral oil placebo; median follow-up 4.9 years; primary endpoint: 5-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, unstable angina); result: 25% relative risk reduction (NNT = 21 over 5 years); secondary endpoint (3-point MACE: CV death + non-fatal MI + non-fatal stroke): 26% relative risk reduction; absolute risk reduction: 4.8% over 5 years; FDA approved Vascepa (icosapentaenoic acid 4g/day) for CV risk reduction in this population in December 2019; controversy: the mineral oil placebo was itself potentially pro-inflammatory (raises LDL-C, reduces absorption of statins) — this remains debated; the REDUCE-IT signal was nonetheless large enough that most cardiologists consider it clinically meaningful; STRENGTH trial contrast: used EPA+DHA (in re-esterified triglyceride form) at 4g/day vs corn oil placebo; found no CV benefit; leading hypothesis for the difference: DHA raises LDL-C and may attenuate EPA's anti-inflammatory effects via competitive substrate effects
−30%
triglyceride reduction at 4g/day — omega-3 fatty acids at high dose (3–4g EPA+DHA/day) consistently reduce fasting triglycerides by 20–50% depending on baseline levels; highest baseline TG = greatest absolute reduction; FDA-approved indications for prescription omega-3s specifically include hypertriglyceridemia (TG ≥500 mg/dL); mechanism: EPA and DHA suppress hepatic VLDL assembly and secretion (reduce de novo lipogenesis and VLDL-TG output); also increase lipoprotein lipase (LPL) activity (the enzyme that clears TG from blood); activate PPARα in the liver (reducing TG synthesis genes); dose-response: 1g EPA+DHA/day: −20–25% TG reduction; 2g/day: −25–30%; 4g/day: −30–45%; caution on LDL-C: DHA (but not pure EPA) raises LDL-C in some individuals, particularly those with high baseline TG; this is because DHA shifts VLDL to larger, less atherogenic LDL particles, but the absolute particle count can rise; in REDUCE-IT, pure EPA (no DHA) did not raise LDL-C; this is one reason cardiologists are increasingly preferring pure EPA formulations for high-risk patients
EPA≠DHA
distinct mechanisms — EPA and DHA are both long-chain omega-3 polyunsaturated fatty acids but they are NOT interchangeable; EPA (20:5n-3): primary anti-inflammatory substrate; competes with arachidonic acid (AA, the omega-6 pro-inflammatory precursor) for COX and LOX enzymes; EPA-derived eicosanoids (prostaglandins E3, thromboxane A3, leukotriene B5) are significantly less pro-inflammatory than AA-derived equivalents (prostaglandin E2, thromboxane A2, leukotriene B4); EPA generates resolvins of the E-series (RvE1, RvE2) — active resolution mediators that shut off the inflammatory cascade; DHA (22:6n-3): primarily structural; makes up 30–40% of neuronal phospholipid bilayers; critical for synaptic membrane fluidity and photoreceptor function; generates D-series resolvins (RvD1-D6) and protectins (PD1, neuroprotectin D1); does not compete with AA as effectively as EPA; ratio insight: the dietary AA:EPA ratio in Western populations averages approximately 20:1 (driven by omega-6 vegetable oils); optimal health is associated with ratios closer to 4:1; omega-3 supplementation shifts this ratio; EPA is more effective per gram at shifting the ratio than DHA; the omega-3 index (% EPA+DHA in red blood cell membranes): optimal is ≥8%; average American is ~4%; most studies associating omega-3 with outcomes use the omega-3 index as the exposure variable
Oxidation
the quality problem no one talks about — fish oil is extraordinarily susceptible to oxidation; polyunsaturated fatty acids (EPA has 5 double bonds; DHA has 6) are thermodynamically unstable at room temperature; primary oxidation produces lipid peroxides (measured as peroxide value, PV); secondary oxidation produces aldehydes including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) — measured as anisidine value (AV); TOTOX score = 2×PV + AV; GOED (Global Organization for EPA and DHA Omega-3s) voluntary standard: PV ≤5 mEq/kg, AV ≤20, TOTOX ≤26; Ritter 2013 (Journal of Nutritional Science): analysis of 171 New Zealand retail omega-3 products; 83% exceeded Norwegian quality standards; 50% had PV above acceptable limits; the clinical significance of oxidized fish oil: 4-HNE is pro-inflammatory and cytotoxic; consuming oxidized fish oil may produce the opposite of the intended effect; practical test: open a fish oil capsule and smell it; mild fishy odor = normal; rancid, stale, or paint-like odor = likely oxidized; quality indicators: TOTOX score should be disclosed by manufacturers; best practices: refrigerate after opening; choose small-batch brands with third-party testing; enteric coating doesn't prevent oxidation — it just hides it; consume within 3 months of opening
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
Omega-3 Form Comparison: What Actually Matters for Absorption
| Form | Absorption vs Standard | Source | Notes |
|---|
| Re-esterified Triglyceride (rTG) | 70% better than ethyl ester (Dyerberg 2010) | Fish oil; most expensive fish oil form | Best-absorbed fish oil form; closely mimics natural fatty acid structure in food; look for "triglyceride form" or "rTG" on label |
| Natural Triglyceride (from fatty fish) | Baseline reference (100%) | Whole fatty fish (salmon, sardines, mackerel, herring) | Food-form omega-3 is the gold standard; wild salmon 2.2g EPA+DHA per 100g; eating fish 2–3×/week provides ~1.5–2g EPA+DHA/week |
| Phospholipid (krill oil) | ~50% better than ethyl ester in some studies | Antarctic krill (Euphausia superba) | Phospholipid form has good CNS uptake; krill also contains astaxanthin (antioxidant that protects EPA+DHA from oxidation); dose per capsule is lower — need more capsules for therapeutic dose; more expensive per gram |
| Ethyl Ester (most supplements) | Reference (lowest) | Concentrated fish oil — most common pharmaceutical and retail form | Vascepa (icosapentaenoic acid in REDUCE-IT) IS an ethyl ester; absorption is enhanced significantly when taken with a high-fat meal; standard low-dose supplements (1g) often taken without food → poor absorption |
| Algae Oil (DHA dominant) | Comparable to fish oil | Microalgae (Schizochytrium, Crypthecodinium) — where fish get their omega-3 | Vegan; sustainable; typically DHA-dominant with low EPA; best vegan source; brands: Nordic Naturals Algae DHA, Ovega-3 |
Omega-3 Protocol by Goal
Baseline anti-inflammatory + general health (1–2g EPA+DHA/day): re-esterified triglyceride fish oil OR krill oil; take with the largest meal of the day (fat enhances absorption significantly — up to 3× for ethyl esters); refrigerate after opening; check for TOTOX score on brand website; eating fatty fish (salmon, sardines, mackerel, herring) 2–3× per week provides equivalent or better intake from whole-food omega-3.
Triglyceride reduction (2–4g EPA+DHA/day): prescription omega-3s (Lovaza, Omacor) at 4g/day are FDA-approved for this indication; alternatively, high-quality rTG form fish oil 2–4g/day; recheck fasting triglycerides at 8–12 weeks; this dose range consistently achieves 25–45% TG reduction.
Cardiovascular risk reduction (post-REDUCE-IT): for patients meeting REDUCE-IT criteria (on statin, elevated TG ≥150 mg/dL, established CVD or diabetes + risk factors): pure EPA (icosapentaenoic acid) at 4g/day is the evidence-supported choice; requires prescription (Vascepa in the US); discuss with cardiologist; do NOT substitute standard mixed EPA+DHA fish oil at this indication — STRENGTH showed no benefit.
Brain/DHA: DHA-dominant preparation for pregnant women (600mg DHA/day), infants, and individuals focused on cognitive support; algae oil preferred for vegans; combination EPA+DHA is reasonable for most adults using 1–2g/day for general brain support.
Omega-3 index testing: OmegaQuant (home finger-prick test) measures RBC omega-3 index; target ≥8% (most people are 3–5%); retesting at 3–4 months after supplementation confirms absorption and guides dose adjustment; this is the most objective way to know if your current supplement and dose are actually working.
rTG Fish Oil →
Krill Oil →
More evidence-based protocols
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.